Lidocaine vs aprindine
Coma · patients with myocardial infarction
It is very uncertain whether lidocaine changes coma compared with aprindine (very low certainty).
1 finding from 1 review
- RR 3 [0.13, 67.06]1 study · 24 participantsVery low
Findings
What do systematic reviews say?
771 questions · 791 findings · 66 reviews
No studies found 207 · 26.2%GRADE not reported 47 · 5.9%Very low 172 · 21.7%Low 211 · 26.7%Moderate 107 · 13.5%High 47 · 5.9%
Lidocaine vs aprindine
Seizures · patients with myocardial infarction
It is very uncertain whether lidocaine changes seizures compared with aprindine (very low certainty).
1 finding from 1 review
- RR 5 [0.27, 94.34]1 study · 24 participantsVery low
Lidocaine vs aprindine
Specific behaviour ‐ agitation · patients with myocardial infarction
It is very uncertain whether lidocaine changes agitation compared with aprindine (very low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.77]1 study · 24 participantsVery low
Lidocaine vs pirmenol
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lidocaine vs pirmenol
Cardiac mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lidocaine vs pirmenol
Overall survival at 30 days after myocardial infarction · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lidocaine vs pirmenol
Ventricular fibrillation · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lidocaine vs pirmenol
Adverse events (any type) and safety of sealant · patients with myocardial infarction
It is very uncertain whether lidocaine changes safety (AEs; adverse drug reaction): any adverse event compared with pirmenol (very low certainty).
1 finding from 1 review
- RR 1.11 [0.47, 2.6]1 study · 19 participantsVery low
Lidocaine vs placebo or no intervention
Adverse events (AEs; adverse drug reaction): sinus bradycardia · patients with acute myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinus bradycardia compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- RR 1.09 [0.66, 1.8]8 studies · 2549 participantsVery low
Lidocaine vs placebo or no intervention
Adverse events (AEs; adverse drug reaction): drowsiness/dizziness · patients with acute myocardial infarction
Lidocaine may leads to higher adverse events (AEs; adverse drug reaction): drowsiness/dizziness compared with placebo or no intervention (low certainty).
1 finding from 1 review
- RR 3.85 [2.29, 6.47]6 studies · 2533 participantsLow
Lidocaine vs disopyramide
All‐cause mortality · patients with myocardial infarction
It is very uncertain whether lidocaine changes all‐cause mortality compared with disopyramide (very low certainty).
1 finding from 1 review
- RR 1.39 [0.47, 4.13]2 studies · 144 participantsVery low
Lidocaine vs disopyramide
Cardiac mortality · patients with myocardial infarction
It is very uncertain whether lidocaine changes cardiac mortality compared with disopyramide (very low certainty).
1 finding from 1 review
- RR 1.02 [0.21, 4.87]2 studies · 144 participantsVery low
Intervention not reported
Survival · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes survival (very low certainty).
1 finding from 1 review
- Prophylactic gastrojejunostomy for unresectable periampullary carcinoma 2013 · Cochrane Headline outcomes onlyHR 1.02 [0.84, 1.25]2 studies · 152 participantsVery low
Intervention not reported
Gastric outlet obstruction Clinical symptoms of vomiting with confirmation of the gastric outlet obstruction by radiological or endoscopic investigations · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes gastric outlet obstruction Clinical symptoms of vomiting with… (very low certainty).
1 finding from 1 review
- Prophylactic gastrojejunostomy for unresectable periampullary carcinoma 2013 · Cochrane Headline outcomes onlyRR 0.1 [0.03, 0.37]2 studies · 152 participantsVery low
Intervention not reported
Operating time · patients with unresectable periampullary carcinoma
1 finding from 1 review
- Prophylactic gastrojejunostomy for unresectable periampullary carcinoma 2013 · Cochrane Headline outcomes onlyno estimate extracted1 study · 87 participantsVery low
Intervention not reported
Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to lower febrile neutropenia Rates of patients (moderate certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 0.27 [0.11, 0.7]6 studies · 2073 participantsModerate
Intervention not reported
Injection‐site reaction Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to higher injection‐site reaction Rates of patients (moderate certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 3.59 [2.33, 5.53]2 studies · 262 participantsModerate
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 0.32 [0.13, 0.77]8 studies · 2143 participantsLow
Intervention not reported
Infection‐related mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in infection‐related mortality Rates of patients (low certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 0.14 [0.02, 1.29]8 studies · 2143 participantsLow
Intervention not reported
Severe neutropenia (WHO grade IV) Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in severe neutropenia (WHO grade IV) Rates of patients (moderate certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 0.44 [0.17, 1.18]4 studies · 712 participantsModerate